Market capitalization | $350.00k |
Enterprise Value | $-5.92m |
P/E (TTM) P/E ratio | 0.00 |
EV/FCF (TTM) EV/FCF | 0.63 |
EV/Sales (TTM) EV/Sales | -1.64 |
P/S ratio (TTM) P/S ratio | 0.10 |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $3.62m |
EBIT (operating result TTM) EBIT | $-18.80m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Adamis Pharmaceuticals Corporation:
1 Analyst has issued a forecast Adamis Pharmaceuticals Corporation:
Sep '23 |
+/-
%
|
||
Revenue | 3.62 3.62 |
71%
71%
|
|
Gross Profit | -1.90 -1.90 |
313%
313%
|
|
EBITDA | -18 -18 |
39%
39%
|
EBIT (Operating Income) EBIT | -19 -19 |
42%
42%
|
Net Profit | -22 -22 |
61%
61%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. The company was founded in June 2006 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Ebrahim Versi |
Employees | 11 |
Founded | 2006 |
Website | www.adamispharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.